Cargando…

Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer

In cancer patients, a high pre-treatment neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival outcomes. Significant variation in the magnitude of this association has been observed between studies, but sources of this variation are poorly understood. Here, we explore differences i...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Rachel, Kanetsky, Peter A., Egan, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928022/
https://www.ncbi.nlm.nih.gov/pubmed/31873162
http://dx.doi.org/10.1038/s41598-019-56218-z
_version_ 1783482391514316800
author Howard, Rachel
Kanetsky, Peter A.
Egan, Kathleen M.
author_facet Howard, Rachel
Kanetsky, Peter A.
Egan, Kathleen M.
author_sort Howard, Rachel
collection PubMed
description In cancer patients, a high pre-treatment neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival outcomes. Significant variation in the magnitude of this association has been observed between studies, but sources of this variation are poorly understood. Here, we explore differences in the prognostic potential of NLR between patient subgroups stratified by demographic and clinical characteristics using a retrospective cohort of 5,363 patients treated at Moffitt Cancer Center (Tampa, FL). We identify patients for whom NLR has maximum prognostic potential via adjusted hazard ratios (HRs) calculated using multivariable Cox proportional hazards models and area under the curve analysis. NLR demonstrates stronger associations (HRs > 2) with survival among African-American patients, patients receiving radiation therapy, stage IV patients, and melanoma patients when compared with the overall study population (HR = 1.58). Sensitivity and specificity of NLR as a prognostic marker are also higher in these patient subgroups, and increase further with combinations of multiple “high-risk” demographic or clinical characteristics. In summary, NLR may have greater prognostic value in patients with certain demographic and clinical features. Future prospective studies could validate this hypothesis, after further characterization of populations in which NLR has maximum prognostic potential and the identification of meaningful thresholds for risk stratification.
format Online
Article
Text
id pubmed-6928022
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69280222019-12-27 Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer Howard, Rachel Kanetsky, Peter A. Egan, Kathleen M. Sci Rep Article In cancer patients, a high pre-treatment neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival outcomes. Significant variation in the magnitude of this association has been observed between studies, but sources of this variation are poorly understood. Here, we explore differences in the prognostic potential of NLR between patient subgroups stratified by demographic and clinical characteristics using a retrospective cohort of 5,363 patients treated at Moffitt Cancer Center (Tampa, FL). We identify patients for whom NLR has maximum prognostic potential via adjusted hazard ratios (HRs) calculated using multivariable Cox proportional hazards models and area under the curve analysis. NLR demonstrates stronger associations (HRs > 2) with survival among African-American patients, patients receiving radiation therapy, stage IV patients, and melanoma patients when compared with the overall study population (HR = 1.58). Sensitivity and specificity of NLR as a prognostic marker are also higher in these patient subgroups, and increase further with combinations of multiple “high-risk” demographic or clinical characteristics. In summary, NLR may have greater prognostic value in patients with certain demographic and clinical features. Future prospective studies could validate this hypothesis, after further characterization of populations in which NLR has maximum prognostic potential and the identification of meaningful thresholds for risk stratification. Nature Publishing Group UK 2019-12-23 /pmc/articles/PMC6928022/ /pubmed/31873162 http://dx.doi.org/10.1038/s41598-019-56218-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Howard, Rachel
Kanetsky, Peter A.
Egan, Kathleen M.
Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
title Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
title_full Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
title_fullStr Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
title_full_unstemmed Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
title_short Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
title_sort exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928022/
https://www.ncbi.nlm.nih.gov/pubmed/31873162
http://dx.doi.org/10.1038/s41598-019-56218-z
work_keys_str_mv AT howardrachel exploringtheprognosticvalueoftheneutrophiltolymphocyteratioincancer
AT kanetskypetera exploringtheprognosticvalueoftheneutrophiltolymphocyteratioincancer
AT egankathleenm exploringtheprognosticvalueoftheneutrophiltolymphocyteratioincancer